Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis

Expert Review of Clinical Pharmacology

Volumn 6, Issue 2, 2013, Pages 123-137

  Zhang, Xiaoping ^a   Morcos, Peter N ^a   Saito, Tomohisa ^b   Terao, Kimio ^b  

^a HOFFMANN LA ROCHE INC   (United States)

^b CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Actemra ; C reactive protein; clinical pharmacology; exposure response relationship; IL 6; IL 6 receptor; pharmacokinetics; systemic juvenile idiopathic arthritis; tocilizumab

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; CYCLOSPORIN; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SERUM AMYLOID A; STAT PROTEIN; TOCILIZUMAB;

AREA UNDER THE CURVE; ARTICLE; CORTICOSTEROID THERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; GASTROINTESTINAL TOXICITY; HEMATOPOIESIS; HUMAN; INFECTION; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS; MAXIMUM PLASMA CONCENTRATION; MEDIASTINUM DISEASE; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; PHARYNGITIS; PROTEIN BLOOD LEVEL; RHINOPHARYNGITIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, ANIMAL; RECEPTORS, INTERLEUKIN-6; TREATMENT OUTCOME;

EID: 84874916146     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.13.1     Document Type: Article

References (50)

1. de Benedetti F, Schneider R. Systemic juvenile idiopathic arthritis. In: Textbook of Pediatric Rheumatology (6th Edition). Cassidy JT, Petty RE, Laxer R, Lindsley C (Eds). Elsevier, PA, USA, 236-248 (2012
2. Kelly A, Ramanan AV. Recognition and management of macrophage activation syndrome in juvenile arthritis. Curr. Opin. Rheumatol. 19(5), 477-481 (2007
3. Woo P. Systemic juvenile idiopathic arthritis: Diagnosis, management, and outcome. Nat. Clin. Pract. Rheumatol. 2(1), 28-34 (2006
4. Behrens EM, Beukelman T, Gallo L et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: Data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR J. Rheumatol. 35(2), 343-348 (2008
5. Symmons DP, Jones M, Osborne J, Sills J, Southwood TR, Woo P. Pediatric rheumatology in the United Kingdom: Data from the British Pediatric Rheumatology Group National Diagnostic Register. J. Rheumatol. 23(11), 1975-1980 (1996
6. Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing? Arthritis Rheum. 39(8), 1385-1390 (1996
7. Gäre BA, Fasth A. Epidemiology of juvenile chronic arthritis in southwestern Sweden: A 5-year prospective population study. Pediatrics 90(6), 950-958 (1992
8. Fujikawa S, Okuni M. Clinical analysis of cases with juvenile rheumatoid arthritis: Results of a nationwide retrospective survey in Japan. Acta Paediatr. Jpn. 39(2), 245-249 (1997
9. Seth V, Kabra SK, Semwal OP, Jain Y. Clinico-immunological profile in juvenile rheumatoid arthritis: An Indian experience. Ind J. Pediatr. 63, 293-300 (1996
10. Woo P, Southwood TR, Prieur AM et al. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 43(8), 1849-1857 (2000
11. Horneff G, De Bock F, Foeldvari I et al.; German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): Preliminary data from the German JIA Registry. Ann. Rheum. Dis. 68(4), 519-525 (2009
12. Prince FH, Twilt M, ten Cate R et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: The Dutch national register. Ann. Rheum. Dis. 68(5), 635-641 (2009
13. Gattorno M, Piccini A, Lasigliè D et al. The pattern of response to anti-interleukin-.1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 58(5), 1505-1515 (2008).
14. Lequerré T, Quartier P, Rosellini D et al.; Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: Preliminary experience in France. Ann. Rheum. Dis. 67(3), 302-308 (2008
15. Quartier P, Allantaz F, Cimaz R et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-.1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann. Rheum. Dis. 70(5), 747-754 (2011
16. RoActemra® (tocilizumab). Summary of product characteristics. Roche Registration Limited, Welwyn Garden City, UK (2011
17. Actemra® (tocilizumab injection, for intravenous infusion). Genentech, CA, USA (2011
18. Actemra® (tocilizumab). Chugai Pharmaceutical Co. Ltd, Tokyo, Japan (2008
19. Zhang X. Summary of clinical pharmacology studies for tocilizumab in patients with systemic juvenile idiopathic arthritis. Regulatory filing document on file at Hoffmann-LaRoche (2010
20. Woo P, Wilkinson N, Prieur AM et al. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: Proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res. Ther. 7(6), R1281-R1288 (2005)
21. Yokota S, Miyamae T, Imagawa T et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 52(3), 818-825 (2005
22. Yokota S, Imagawa T, Mori M et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: A randomised, double-blind, placebo-controlled, withdrawal Phase III trial. Lancet (9617), 998-1006 (2008 (25), 2385-2395 (2012
23. Zhang A, London R, Schulz FM et al. Human liver progenitor cell lines are readily established from non-tumorous tissue adjacent to hepatocellular carcinoma. Stem Cells Dev. 19(8), 1277-1284 (2010
24. Sato K, Tsuchiya M, Saldanha J et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53(4), 851-856 (1993
25. Hushaw LL, Sawaqed R, Sweis G et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther. Clin. Risk Manag. 6, 143-152 (2010
26. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb. Exp. Pharmacol. 181, 151-160 (2008
27. Le Goff B, Blanchard F, Berthelot JM, Heymann D, Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint. Bone. Spine 77(3), 201-205 (2010
28. Rose-John S, Waetzig GH, Scheller J, Grötzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin. Ther. Targets (5), 613-624 (2007
29. Sebba A. Tocilizumab: The first interleukin-.6-receptor inhibitor. Am. J. Health. Syst. Pharm. 65(15), 1413-1418 (2008
30. De Benedetti F, Pignatti P, Gerloni V et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J. Rheumatol. 24(7), 1403-1409 (1997
31. de Benedetti F, Massa M, Robbioni P, Ravelli A, Burgio GR, Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 34(9), 1158-1163 (1991
32. Pignatti P, Vivarelli M, Meazza C, Rizzolo MG, Martini A, De Benedetti F. Abnormal regulation of interleukin 6 in systemic juvenile idiopathic arthritis. J. Rheumatol. 28(7), 1670-1676 (2001
33. De Benedetti F, Martini A. Is systemic juvenile rheumatoid arthritis an interleukin mediated disease? J. Rheumatol. 25(2), 203-207 (1998
34. Keul R, Heinrich PC, Müller-newen G, Muller K, Woo P. A possible role for soluble IL-6 receptor in the pathogenesis of systemic onset juvenile chronic arthritis. Cytokine 10(9), 729-734 (1998
35. De Benedetti F, Rucci N, Del Fattore A et al. Impaired skeletal development in interleukin-6-transgenic mice: A model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 54(11), 3551-3563 (2006
36. De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. Curr. Opin. Rheumatol. 21(5), 533-537 (2009
37. Zhang X, Peck R. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis. Expert Rev. Clin. Pharmacol. 4(5), 539-558 (2011
38. Nakamura I, Omata Y, Naito M, Ito K. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J. Rheumatol. 36(2), 459-460 (2009
39. Biffl WL, Moore EE, Moore FA, Barnett CC Jr. Interleukin-6 suppression of neutrophil apoptosis is neutrophil concentration dependent. J. Leukoc. Biol. 58(5), 582-584 (1995
40. McLoughlin RM, Hurst SM, Nowell MA et al. Differential regulation of neutrophilactivating chemokines by IL-6 and its soluble receptor isoforms. J. Immunol. 172(9), 5676-5683 (2004
41. Robak T, Gladalska A, Stepien H, Robak E. Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis. Mediators Inflamm. 7(5), 347-353 (1998
42. Zhang X, Morcos AP, de Benedetti F et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of tocilizumab in patients with systemic juvenile idiopathic arthritis. Presented at: European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, London, UK, 25-28 May 2011
43. Uchiyama Y, Yoshida H, Koike N et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int. Immunopharmacol. 8(11), 1595-1601 (2008
44. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10), 3959-3964 (2008
45. Morcos P, Mcintyre C, Bittner B, Rowell L, Hussain Z, Zhang X. Pharmacokinetics (PK) and pharmacodynamics (PD) of single subcutaneous doses of tocilizumab (TCZ) administered with and without rHuPH20, a recombinant human hyaluronidase, in healthy volunteers. Clin. Pharmacol. Ther. 89, S57 (2011
46. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 89(5), 735-740 (2011
47. Nishimoto N, Yoshizaki K, Maeda K et al. Toxicity, pharmacokinetics, and dosefinding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. J. Rheumatol. 30(7), 1426-1435 (2003
48. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J. Clin. Pharmacol. 50(7), 754-766 (2010
49. Sikora KA, Grom AA. Update on the pathogenesis and treatment of systemic idiopathic arthritis. Curr. Opin. Pediatr. 23(6), 640-646 (2011
50. Quartier P. Current treatments for juvenile idiopathic arthritis. Joint. Bone. Spine (6), 511-516 (2010